Effect of Camostate mesylate on the outcome of Coronavirus (COVID-19)-induced pneumonia

Phase 3

Recruiting

Conditions: J12.89
Other viral pneumonia
Condition 1: Coronavirus (COVID-19)-induced pneumonia. Condition 2: COVID-19.
COVID-19, virus identified
U07.1

Registration Number: IRCT20200317046797N1

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 40

Inclusion Criteria

Moderate to severe 2019-nCoV-infected patients
Being at the age of 18 to 80 years
Patients or authorized family members volunteered to participate in this study and signed informed consent.
Both genders
pulmonary involvement in CT scan
PCR positive

Exclusion Criteria

Patient with elevated liver enzymes 3 time the upper limit of normal
Patients who are participating in other drug clinical trials
Patients with active pulmonary tuberculosis
Patients with definite bacterial and fungal infections
Pregnant or lactating women
Patient with active thrombotic event

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ung symptoms. Timepoint: At baseline (before intervention) and after drug administration. Method of measurement: Lung CT scan.;Hospitalization period. Timepoint: At baseline and discharge time. Method of measurement: Counting the day.;Mortality rate. Timepoint: At baseline and discharge time. Method of measurement: Observation.;Need for intubation. Timepoint: At baseline and discharge time. Method of measurement: Observation.

Secondary Outcome Measures